You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
13 October 2021
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
27 January 2021
NanoViricides, Inc.: Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.’s President, Dr. Anil Diwan
17 November 2020
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 – Has Sufficient Cash, Coronavirus Drug Development Progress
16 September 2020
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19
21 July 2020
NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020
13 July 2020
NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock
9 July 2020
NanoViricides, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock
30 June 2020
NanoViricides Announces Addition to Russell Microcap(R) Index
20 May 2020
NanoViricides, Inc.: Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus
16 March 2020
NanoViricides, Inc.: Coronavirus Drug Development Update from NanoViricides, Inc.